EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical outcomes and safety of preservative-free diclofenac sodium eye drops in SPT-assisted transepithelial photorefractive keratectomy

Huang Zhang, Ming-Ming Li, Shuang Qiu

Frontiers in Pharmacology · 15.04.2026 · 17

DOI: 10.3389/fphar.2026.1781133 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 15.04.2026. Verfasst von Huang Zhang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Zhongshan Torch Development Zone People's Hospital, Zhongshan, Guangdong, China. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Early postoperative pain and epithelial recovery remain important determinants of patient experience after surface ablation refractive surgery. Evidence comparing topical nonsteroidal anti-inflammatory drug (NSAID) options in Smart Pulse Technology (SPT)-assisted transepithelial photorefractive keratectomy (TransPRK) is limited.

Methods

This retrospective cohort study included consecutive patients who underwent SPT-assisted TransPRK between January 2022 and December 2025. Patients received either standard postoperative care plus pranoprofen 0.1% eye drops (control group) or preservative-free diclofenac sodium 0.1% eye drops (PF diclofenac; observation group), administered four times daily for 3 days. Pain was assessed using the visual analog scale (VAS; 0–10) at 2, 24, 48, and 72 h. Secondary outcomes included time to complete epithelialization, time to bandage contact lens (BCL) removal, corneal haze grading, ocular surface and inflammatory signs, and adverse events.

Results

A total of 239 patients were analyzed (control, n = 118; observation, n = 121). The observation group had significantly lower VAS pain scores at 2 h (5.40 ± 1.70 vs. 4.80 ± 1.60; P = 0.005), 24 h (4.20 ± 1.60 vs. 3.40 ± 1.50; P < 0.001), 48 h (2.80 ± 1.30 vs. 2.10 ± 1.20; P < 0.001), and 72 h (1.60 ± 1.00 vs. 1.20 ± 0.90; P = 0.001). A higher proportion of patients in the observation group achieved mild pain (VAS ≤ 3) at 24 h (53.7% vs. 38.1%; P = 0.016). Time to complete epithelialization (4.05 ± 0.88 vs. 4.32 ± 0.92 days; P = 0.021) and BCL removal (4.25 ± 0.90 vs. 4.56 ± 0.98 days; P = 0.012) were shorter in the observation group. Corneal haze and adverse events were comparable between groups, and no serious adverse events were observed.

Conclusion

In SPT-assisted TransPRK, PF diclofenac was associated with improved early pain control and modestly faster epithelial recovery, without detectable differences in haze or short-term safety compared with pranoprofen.

Schlagwörter

Stichwörter der Autor:innen

nonsteroidal anti-inflammatory drugpostoperative painpranoprofenpreservative-free diclofenac sodiumsmart pulse technologytransepithelial photorefractive keratectomy

Autor:innen und Institutionen

  • Department of Ophthalmology, Zhongshan Torch Development Zone People's Hospital, Zhongshan, Guangdong, China.

Zitieren

APA

Zhang, H., Li, M. M., & Qiu, S. (2026). Clinical outcomes and safety of preservative-free diclofenac sodium eye drops in SPT-assisted transepithelial photorefractive keratectomy. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1781133

Vancouver

Zhang H, Li MM, Qiu S. Clinical outcomes and safety of preservative-free diclofenac sodium eye drops in SPT-assisted transepithelial photorefractive keratectomy. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1781133

BibTeX
@article{Zhang2026,
  author = {Zhang, Huang and Li, Ming-Ming and Qiu, Shuang},
  title = {Clinical outcomes and safety of preservative-free diclofenac sodium eye drops in SPT-assisted transepithelial photorefractive keratectomy},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1781133}
}
Kostenlos starten →